Personalis, Inc. Hits New 52-Week High of $16.39, Up 1065.91%

Personalis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 16.39 on July 17, 2026. This achievement marks a remarkable increase from its 52-week low of USD 3.84, reflecting a staggering one-year performance of 1065.91%, significantly outpacing the S&P 500's performance of 18.43% during the same period. With a market capitalization of USD 663 million, Personalis operates in a competitive industry characterized by rapid advancements and innovation. The company's financial metrics indicate a challenging landscape, as it currently reports a negative return on equity of -31.12% and a debt-to-equity ratio of -0.88. Additionally, the stock does not offer a dividend yield, aligning with its growth-focused strategy. As Personalis continues to navigate the dynamic biotechnology market, its recent price movement underscores the volatility and potential within the sector, highlighting the company's journey and performance over the past year.